



June 11, 2015

Lilly Announces Webcast to Discuss Ixekizumab Phase III Data

INDIANAPOLIS, June 11, 2015 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) will host a webcast on June 23 to discuss three pivotal Phase III studies investigating ixekizumab for the treatment of moderate-to-severe plaque psoriasis. Data from the UNCOVER-1, -2 and -3 clinical studies will be discussed. In March, data from UNCOVER-1 was presented at the American Academy of Dermatology annual meeting. Earlier this month, additional data from UNCOVER-1 as well as data from UNCOVER-2 and -3 were presented at the World Congress of Dermatology.

The webcast will begin at 10:00 a.m. Eastern Daylight Time. A live audio webcast will be available on the "Webcasts & Presentations" section of Lilly's investor website at <http://investor.lilly.com/events.cfm>. A replay will be available for approximately one week.

About Ixekizumab

Ixekizumab is a monoclonal antibody with high affinity and specificity that binds to and neutralizes the pro-inflammatory cytokine interleukin-17A (IL-17A). In psoriasis, IL-17A plays a major role in driving excess keratinocyte (skin cell) proliferation and activation. Ixekizumab does not bind to cytokines IL-17B, IL-17C, IL-17D, IL-17E or IL-17F. Ixekizumab is administered via subcutaneous injection (under the skin). Ixekizumab is also in clinical development for the treatment of psoriatic arthritis.

About Ixekizumab UNCOVER Phase III Trials

The UNCOVER studies are double-blind, multicenter, Phase III studies evaluating more than 3,800 patients with moderate-to-severe psoriasis in 18 countries. UNCOVER-1 compared the safety and efficacy of different dosing regimens of ixekizumab with placebo after 12 weeks and 60 weeks of treatment. The UNCOVER-2 and -3 studies assigned patients to receive either placebo, etanercept (50 mg twice a week) or ixekizumab (80 mg every two or four weeks) for 12 weeks, following a 160 mg starting dose.

About Eli Lilly and Company

Lilly is a global healthcare leader that unites caring with discovery to make life better for people around the world. We were founded more than a century ago by a man committed to creating high-quality medicines that meet real needs, and today we remain true to that mission in all our work. Across the globe, Lilly employees work to discover and bring life-changing medicines to those who need them, improve the understanding and management of disease, and give back to communities through philanthropy and volunteerism. To learn more about Lilly, please visit us at www.lilly.com and <http://newsroom.lilly.com/social-channels>. P-LLY

Refer to:

Tim Coulom; tim.coulom@lilly.com; (317) 771-2241 (Media)
Lauren Zierke; lauren_zierke@lilly.com; (317) 277-6524 (Media)
Phil Johnson; johnson_philip_l@lilly.com; (317) 655-6874 (Investors)



Logo - <http://photos.prnewswire.com/prnh/20031219/LLYLOGO>

To view the original version on PR Newswire, visit: <http://www.prnewswire.com/news-releases/lilly-announces-webcast-to->

[discuss-ixekizumab-phase-iii-data-300097859.html](https://www.fda.gov/oc/ohrt/discuss-ixekizumab-phase-iii-data-300097859.html)

SOURCE Eli Lilly and Company

News Provided by Acquire Media